ProNAi Therapeutics Raises $59.5 Million Series D Financing

Plymouth, MI—April 21, 2014. ProNAi Therapeutics, Inc., a developer of novel nucleic acid therapeutics, announced the closing of an oversubscribed $59.5 million Series D financing. The round was led by Vivo Capital of Palo Alto, CA and included other new investors Frazier Healthcare Ventures, OrbiMed Advisors, Adams Street Partners, RA Capital Management, Caxton Alternative Management, Hopen Life Science Ventures, Sectoral Asset Management, and Janus Capital Management LLC.

Read more: ProNAi Therapeutics Raises $59.5 Million Series D Financing